Toxic metals have long been associated with cardiovascular disease. Removing these metals with chelation may help treat cardiovascular disease and prevent future life-threatening events like heart attacks. Jonathan Collin, MD, is an experienced practitioner in the field of chelation therapy and an expert in using chelation for cardiovascular treatment. To learn whether you can consider chelation together with your existing cardiovascular care, call one of the offices in Port Townsend or Kirkland, Washington.
Your body is constantly exposed to toxic metals found in the air, water, land, and food, as plants and animals also absorb environmental toxins. As these toxic metals or heavy metals accumulate in tissues throughout your body, they cause damage and disease.
During chelation therapy, Dr. Collin intravenously administers a medication called EDTA. Once EDTA enters your bloodstream, it binds with toxic metals and certain minerals and then carries them out of your body.
Chelation helps treat cardiovascular disease by eliminating the toxic metals that are associated with heart and vascular problems.
A study published in The Lancet in March 2018 found that low-level lead exposure is linked with conditions, such as high blood pressure, hardening of the arteries, and coronary artery disease. Additionally, lead exposure increases the risk of premature death from cardiovascular disease.
Chelation therapy removes several toxic metals known to contribute to cardiovascular disease. Cadmium, which is found in tobacco, air, and food, increases your risk for coronary artery disease. Exposure to arsenic and copper is also associated with a higher chance of developing coronary artery disease.
Emerging studies suggest that like lead, it only takes a low level of exposure to cadmium, arsenic, and copper to put your health at risk.
The National Institutes of Health sponsored a study — the Trial to Assess Chelation Therapy, or TACT — to test whether chelation therapy with EDTA and/or high-dose vitamin therapy might treat cardiovascular disease. The medical team recruited 1708 patients, all aged 50 or older, who had suffered a prior heart attack.
Some of the participants received 40 EDTA intravenous (IV) infusions over the course of 28 months. The first 30 infusions were administered weekly, while the last 10 were infused every two to eight weeks. All the study participants were then followed for five years.
The results of the study show that those receiving chelation had an 18% reduced risk of developing future cardiac events such as angina (chest pain), heart attacks, and strokes.
The patients who received chelation therapy combined with supplemental vitamins and minerals had even better results: Their risk of cardiovascular events was 26% less compared to those who received chelation without supplements.
Dr. Collin carefully evaluates every patient with cardiovascular disease to determine whether toxic metal treatment can be safely administered along with their other medications and heart treatments. To learn more about your options, call Jonathan Collin, MD